Filing Analysis
Solana Company has entered into an Amended and Restated Sales Agreement to significantly increase its 'at-the-market' (ATM) offering capacity. The company expanded the aggregate gross sales price of shares it can sell from $92.8 million to $250 million.
🚩 Red Flags
- Significant increase in potential share dilution (increasing the cap to $250M is a substantial amount relative to typical micro-cap equity bases)
- Heavy reliance on ATM offerings for capital suggests a need for continuous liquidity
📋 Key Facts
- Agreement date: May 29, 2026
- Offering capacity increased from $92.8 million to $250 million
- Co-sales agents are Clear Street LLC and Maxim Group LLC
- Company has already raised $24,657,697.51 under the prior sales agreement
- Agents' commissions are set at up to 3.00% of aggregate gross proceeds
- Company agreed to reimburse agents for legal expenses up to $75,000
Solana Company reported the voting results of its Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected six directors, ratified the appointment of CBIZ CPAs P.C. as the independent auditor for 2026, and reconstituted the audit committee.
🚩 Red Flags
- High concentration of executive duties: Agustina Gani Tjandrasuwita holds four key officer positions simultaneously (CFO, COO, Treasurer, and Secretary), which is a common governance risk in micro-cap companies.
📋 Key Facts
- Elected four directors (Joseph Chee, Blane Walter, Edward M. Straw, Cosmo Jiang) and two additional directors (Michel Lee, Sergio Mello) to serve one-year terms.
- Ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,738,836 votes in favor.
- Reconstituted the audit committee of the Board of Directors to consist of Blane Walter (Chair), Edward M. Straw, and Michel Lee.
- Agustina Gani Tjandrasuwita signed the filing as CFO, COO, Treasurer, and Secretary.
Solana Co (HSDT) reported its financial results for the fiscal quarter ended March 31, 2026. The filing includes a press release as an exhibit detailing the company's quarterly performance.
🚩 Red Flags
- Inconsistency in registrant name: The header identifies the company as 'SOLANA COMPANY' while the signature block identifies the registrant as 'HELIUS MEDICAL TECHNOLOGIES, INC.'
📋 Key Facts
- Announced financial results for the fiscal quarter ended March 31, 2026
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release dated May 15, 2026, was furnished as Exhibit 99.1
- The filing was signed by Agustina Gani Tjandrasuwita, Chief Operating Officer
Solana Co (HSDT) raised approximately $7.9 million through a registered direct offering of 3,076,922 shares at $2.60 per share. The offering is uniquely structured with a Put Option agreement that allows investors to force a share repurchase at a 7% IRR premium under specific conditions, including delisting notices or financial ratio breaches.
🚩 Red Flags
- Put option agreement creates a potential mandatory cash outflow/liability for the company.
- Put option triggers include 'issuance of a delisting notice', suggesting a high risk of non-compliance with exchange requirements.
- Speculative use of proceeds for 'accumulating SOL' (cryptocurrency) rather than core business operations.
- Tight financial covenant (30% net debt to total capitalization) which, if breached, triggers the put option.
📋 Key Facts
- Issued 3,076,922 shares of Class A common stock at an offering price of $2.60 per share.
- Expected net proceeds of approximately $7.9 million.
- Use of proceeds includes 'accumulating SOL' (cryptocurrency), working capital, and strategic initiatives.
- Entered into Put Option Agreements allowing purchasers to require the company to repurchase shares at the offering price plus a 7.0% IRR per annum.
- Put Option triggers include 12-month and 18-month anniversaries, net debt to total capitalization ratio exceeding 30%, or receipt of a delisting notice.
Solana Co announced the departure of two directors and the immediate appointment of two new directors with significant expertise in digital assets and global investment banking. The board size was increased from seven to nine members as part of this transition ahead of the 2026 Annual Meeting.
📋 Key Facts
- Directors Sherrie Perkins and Paul Buckman will not stand for re-election at the May 21, 2026, Annual Meeting.
- The Board of Directors was expanded from seven to nine members on April 23, 2026.
- Michel Lee, co-founder of Hashkey Group and Cybertech Partners, was appointed to the board.
- Sergio Mello, global head of stablecoin solutions at Anchorage Digital and former Reddit advisor, was appointed to the board.
- The company stated there were no disagreements with the departing directors regarding operations, policies, or practices.
On April 8, 2026, Solana Company and Chief Medical Officer Dr. Antonella Favit-Van Pelt mutually agreed to her immediate separation from the company. The company will provide a lump-sum separation payment of $875,000 in exchange for a release of claims.
🚩 Red Flags
- Immediate effective date of departure (April 8, 2026) suggests a lack of transition period.
- Significant cash outlay of $875,000 for a single executive departure in a micro-cap context.
📋 Key Facts
- Dr. Antonella Favit-Van Pelt resigned as Chief Medical Officer effective April 8, 2026.
- The separation was described as a mutual agreement between the executive and the company.
- The company is obligated to pay a $875,000 lump sum separation payment within ten business days.
- The executive agreed to a waiver and release of all claims against the company.
- Dr. Favit-Van Pelt remains bound by confidential information and invention assignment provisions.
Solana Co (HSDT) has appointed Agustina 'Madelene' Gani Tjandrasuwita as Chief Operating Officer and Deputy Chief Financial Officer, effective April 6, 2026. Ms. Tjandrasuwita brings significant executive experience from the blockchain and cryptocurrency sectors, having previously held senior finance roles at Hedera Hashgraph, Aptos Labs, and Gemini.
📋 Key Facts
- Agustina Tjandrasuwita appointed as COO and Deputy CFO effective April 6, 2026.
- Annual base salary set at $350,000 with a target cash bonus of 40% of base salary.
- Target range for aggregate annual bonus and incentives is $300,000 to $500,000.
- One-time sign-on option award of $75,000 in Class A common stock, vesting over four years.
- The appointee previously served as CFO of Hedera Hashgraph (2024-2026) and Head of Finance at Aptos Labs (2022-2024).
- The filing contains a clerical error, labeling Item 5.02 as 'Results of Operations and Financial Condition' instead of the standard 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers'.
Solana Co (formerly Helius Medical Technologies) issued a press release on March 30, 2026, announcing its financial results for the fiscal quarter and full year ended December 31, 2025.
📋 Key Facts
- The company reported financial results for the period ended December 31, 2025.
- The registrant was formerly known as Helius Medical Technologies, Inc.
- The information was furnished under Item 2.02 and is not deemed 'filed' for regulatory purposes.
- The filing includes a press release as Exhibit 99.1.
Solana Company (formerly Helius Medical Technologies) filed an 8-K under Item 8.01 to disclose its current share count: 52,802,604 shares of common stock outstanding plus 23,930,181 pre-funded warrants. The filing highlights significant potential dilution (~45%) from the warrant overhang and follows a corporate name change from a medical device company to one sharing the name of a prominent cryptocurrency blockchain.
🚩 Red Flags
- Large pre-funded warrant overhang representing ~45% potential dilution relative to current outstanding shares
- Corporate name change from medical technology company to 'Solana Company' — shares the name of a major cryptocurrency blockchain (Solana/SOL), raising concerns about a hype-driven pivot or rebranding strategy
- Stand-alone share count disclosure via 8-K may signal upcoming capital markets activity (secondary offering, warrant exercise, or further dilution)
- Name change combined with share/warrant disclosure pattern is common among micro-caps attempting to attract speculative retail interest
📋 Key Facts
- 52,802,604 shares of common stock issued and outstanding as of February 20, 2026
- 23,930,181 pre-funded warrants to purchase common stock are issued and outstanding
- Total fully-diluted share count is approximately 76.7 million shares (~45% dilution from warrants alone)
- Company recently rebranded from Helius Medical Technologies, Inc. to Solana Company
- Listed on Nasdaq under ticker HSDT; incorporated in Delaware
- Signed by CFO Jeffrey S. Mathiesen